Released May 9, 2024, after the close
10-Q filed May 9, 2024, 39 days after period end · 0000950170-24-056869
Q1 2024 · 10-Q
Revenue$1.93M$1.93M −96.7% vs Q1 2023+14.9% vs Q4 2023
Net Income-$48.00M-$48.00M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.47-$0.47 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$51,068,000N/M
Operating Cash Flow-$33,350,000N/M
Free Cash Flowderived-$33,436,000N/M
Margins · derived
Operating margin-2652.9%−2604.4 pt vs Q1 2023
Net margin-2493.7%−2461.7 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $1.93M | $58.98M | $18.41M | $11.14M |
| Net Income | -$48.00M | -$18.88M | -$65.69M | -$45.09M |
| EPS Diluted | -$0.47 | -$0.19 | -$0.68 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR